Clinical and neurophysiological serial assessments of brentuximab vedotin-associated peripheral neuropathy-Reference-Cited by-同舟云学术

Clinical and neurophysiological serial assessments of brentuximab vedotin-associated peripheral neuropathy

Published:2019-05-06 Issue:11 Volume:60 Page:2806-2809
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Mariotto Sara¹,Tecchio Cristina²,Sorio Marco²,Bertolasi Laura¹,Turatti Marco¹,Tozzi Maria C.¹,Benedetti Fabio²,Cavaletti Guido³^ORCID,Monaco Salvatore¹,Ferrari Sergio¹

Affiliation:

1. Department of Neuroscience, Biomedicine and Movement Sciences, University of Verona, Verona, Italy;

2. Department of Clinical and Experimental Medicine, Hematology and Bone Marrow Transplant Unit, University of Verona, Verona, Italy;

3. Experimental Neurology Unit, School of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2019.1605068

Reference12 articles.

1. The European Medicines Agency Review of Brentuximab Vedotin (Adcetris) for the Treatment of Adult Patients With Relapsed or Refractory CD30+ Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use

2. Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial

3. Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma

4. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial

5. Characterization of the peripheral neuropathy associated with brentuximab vedotin treatment of Mycosis Fungoides and Sézary Syndrome

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Rate and characteristics of inflammatory neuropathies associated with brentuximab vedotin therapy;European Journal of Neurology;2024-03-21

2. The Non-hodgkin Lymphoma Treatment and Side Effects: A Systematic Review and Meta-analysis;Recent Patents on Anti-Cancer Drug Discovery;2024-02

3. Primary Cutaneous CD30-Positive Lymphoproliferative Disorders—Current Therapeutic Approaches with a Focus on Brentuximab Vedotin;Journal of Clinical Medicine;2024-01-31

4. Current drug treatment of myasthenia gravis;Current Opinion in Neurology;2023-08-30

5. Crosstalk of Mast Cells and Natural Killer Cells with Neurons in Chemotherapy-Induced Peripheral Neuropathy;International Journal of Molecular Sciences;2023-08-08